Drug Trial Radar · NCT03103542
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Aug 29, 2017
Primary completion
Sep 4, 2019
Study completion Aug 31, 2020
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Bioverativ Therapeutics Inc.
- First posted
- Apr 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to describe the outcome of Immune Tolerance Induction (ITI) treatment performed with rFVIIIFc within a timeframe of 60 weeks in patients with haemophilia A who have failed previous attempts at tolerization.
Conditions
- Hemophilia A
Interventions
Recombinant coagulation factor (rFVIIIFc)Biological
rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ITI SuccessTime frame: up to 60 weeks
Locations
12 sites in 7 countries. Site status is shown where the registry gives one.
Swedish Orphan Biovitrum Research Site
Washington D.C., District of Columbia
Swedish Orphan Biovitrum Research Site
Hamilton, Canada
Swedish Orphan Biovitrum Research Site
Vancouver, Canada
Swedish Orphan Biovitrum Research Site
Bonn, Germany
Swedish Orphan Biovitrum Research Site
Frankfurt am Main, Germany
Swedish Orphan Biovitrum Research Site
Mörfelden-Walldorf, Germany
Swedish Orphan Biovitrum Research site
Dublin, Ireland
Swedish Orphan Biovitrum Research Site
Ljubljana, Slovenia
Swedish Orphan Biovitrum Research site
Gothenburg, Sweden
Swedish Orphan Biovitrum Research Site
Birmingham, United Kingdom
Swedish Orphan Biovitrum Research Site
Liverpool, United Kingdom
Swedish Orphan Biovitrum Research Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.